Matches in SemOpenAlex for { <https://semopenalex.org/work/W2617820327> ?p ?o ?g. }
- W2617820327 endingPage "56815" @default.
- W2617820327 startingPage "56802" @default.
- W2617820327 abstract "// Xue Wang 1, * , Jun Wang 2, * , Yong Yu 3 , Tonghui Ma 4 , Ping Chen 4, 5 , Bing Zhou 4, 6 and Ran Tao 4, 7 1 Shanghai Institute of Immunology, Shanghai Jiao Tong University School of Medicine, Shanghai, PR China 2 Department of Thoracic Surgery, Hangzhou Municipal Hospital of Traditional Chinese Medicine, Hangzhou, PR China 3 Max Delbrück Center for Molecular Medicine, Berlin, Germany 4 Provincial Key Laboratory of Cardiac Transplantation, Zhejiang Provincial People’s Hospital (ZJPPH), Hangzhou, PR China 5 Department of Obstetrics & Gynecology, Shaoxing Second Municipal Hospital, Shaoxing, PR China 6 Department of Cardiothoracic Surgery, Zhejiang Provincial People’s Hospital (ZJPPH), Hangzhou, PR China 7 Department of Hepatobiliary-Pancreatic & Minimally Invasive Surgery, Zhejiang Provincial People’s Hospital (ZJPPH), Hangzhou, PR China * These authors have contributed equally to this work Correspondence to: Ran Tao, email: taohdac9@yahoo.com Bing Zhou, email: doctorzb@yeah.net Keywords: decitabine, experimental autoimmune encephalomyelitis, cardiac transplantation, T cell proliferation, TET2 Received: March 22, 2017 Accepted: April 25, 2017 Published: May 22, 2017 ABSTRACT Multiple sclerosis (MS) is an autoimmune disease characterized by the dysregulated immune response including innate and adaptive immune responses. Increasing evidence has proven the importance of epigenetic modification in the progression of MS. Recent studies revealed that low-dose decitabine (Dec, 5-Aza-2’-deoxycytidine), which incorporates into replicating DNA and inhibits DNA methylation, could prevent experimental autoimmune encephalomyelitis (EAE) development by increasing the number of regulatory T cells (Tregs). Here, we showed that higher-dose decitabine relative to previous studies could also distinctly protect mice from EAE and allogeneic cardiac transplantation. Mechanistic studies revealed decitabine suppressed innate responses in EAE mice through inhibiting the activation of microglia and monocyte-derived macrophages that contributed to reduce the severity of EAE. Furthermore, differentiation of naïve CD4 + T cells into Th1 and Th17 cells was significantly suppressed by decitabine in vivo and in vitro . Though in vitro studies showed decitabine could induce Treg differentiation, there was no obvious change in the percentage of Tregs in Dec-treated EAE mice. Most importantly, we found that T cell proliferation was potently inhibited in vivo and in vitro by higher-dose decitabine through increased gene expression of the DNA dioxygenase TET2 which facilitated the expression of several cell cycle inhibitors. Collectively, our study provides novel mechanistic insights of using the epigenetic modifying agents in the management of both allo- and auto-immune responses." @default.
- W2617820327 created "2017-06-05" @default.
- W2617820327 creator A5007564557 @default.
- W2617820327 creator A5009981614 @default.
- W2617820327 creator A5013313803 @default.
- W2617820327 creator A5047730128 @default.
- W2617820327 creator A5051480539 @default.
- W2617820327 creator A5057584690 @default.
- W2617820327 creator A5065172118 @default.
- W2617820327 date "2017-05-22" @default.
- W2617820327 modified "2023-10-16" @default.
- W2617820327 title "Decitabine inhibits T cell proliferation via a novel TET2-dependent mechanism and exerts potent protective effect in mouse auto- and allo-immunity models" @default.
- W2617820327 cites W1171241794 @default.
- W2617820327 cites W148320297 @default.
- W2617820327 cites W1546868802 @default.
- W2617820327 cites W1607206274 @default.
- W2617820327 cites W1670953131 @default.
- W2617820327 cites W1676351522 @default.
- W2617820327 cites W1955453756 @default.
- W2617820327 cites W1972296893 @default.
- W2617820327 cites W1977604451 @default.
- W2617820327 cites W1982333846 @default.
- W2617820327 cites W1983019708 @default.
- W2617820327 cites W1992039743 @default.
- W2617820327 cites W2006517495 @default.
- W2617820327 cites W2008823687 @default.
- W2617820327 cites W2009719372 @default.
- W2617820327 cites W2013010265 @default.
- W2617820327 cites W2015678735 @default.
- W2617820327 cites W2017808415 @default.
- W2617820327 cites W2045262404 @default.
- W2617820327 cites W2052522631 @default.
- W2617820327 cites W2070053309 @default.
- W2617820327 cites W2073303752 @default.
- W2617820327 cites W2075180511 @default.
- W2617820327 cites W2077003881 @default.
- W2617820327 cites W2098675621 @default.
- W2617820327 cites W2116041320 @default.
- W2617820327 cites W2116414892 @default.
- W2617820327 cites W2138792571 @default.
- W2617820327 cites W2141615498 @default.
- W2617820327 cites W2147734470 @default.
- W2617820327 cites W2151363901 @default.
- W2617820327 cites W2152014155 @default.
- W2617820327 cites W2153627006 @default.
- W2617820327 cites W2155507662 @default.
- W2617820327 cites W2159443316 @default.
- W2617820327 cites W2162226607 @default.
- W2617820327 cites W2167876561 @default.
- W2617820327 cites W2555691655 @default.
- W2617820327 doi "https://doi.org/10.18632/oncotarget.18063" @default.
- W2617820327 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/5593603" @default.
- W2617820327 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/28915632" @default.
- W2617820327 hasPublicationYear "2017" @default.
- W2617820327 type Work @default.
- W2617820327 sameAs 2617820327 @default.
- W2617820327 citedByCount "27" @default.
- W2617820327 countsByYear W26178203272018 @default.
- W2617820327 countsByYear W26178203272019 @default.
- W2617820327 countsByYear W26178203272020 @default.
- W2617820327 countsByYear W26178203272021 @default.
- W2617820327 countsByYear W26178203272022 @default.
- W2617820327 countsByYear W26178203272023 @default.
- W2617820327 crossrefType "journal-article" @default.
- W2617820327 hasAuthorship W2617820327A5007564557 @default.
- W2617820327 hasAuthorship W2617820327A5009981614 @default.
- W2617820327 hasAuthorship W2617820327A5013313803 @default.
- W2617820327 hasAuthorship W2617820327A5047730128 @default.
- W2617820327 hasAuthorship W2617820327A5051480539 @default.
- W2617820327 hasAuthorship W2617820327A5057584690 @default.
- W2617820327 hasAuthorship W2617820327A5065172118 @default.
- W2617820327 hasBestOaLocation W26178203271 @default.
- W2617820327 hasConcept C104317684 @default.
- W2617820327 hasConcept C126322002 @default.
- W2617820327 hasConcept C143998085 @default.
- W2617820327 hasConcept C150194340 @default.
- W2617820327 hasConcept C190727270 @default.
- W2617820327 hasConcept C203014093 @default.
- W2617820327 hasConcept C2780235182 @default.
- W2617820327 hasConcept C2911091166 @default.
- W2617820327 hasConcept C55493867 @default.
- W2617820327 hasConcept C556039675 @default.
- W2617820327 hasConcept C71924100 @default.
- W2617820327 hasConcept C86803240 @default.
- W2617820327 hasConcept C8891405 @default.
- W2617820327 hasConceptScore W2617820327C104317684 @default.
- W2617820327 hasConceptScore W2617820327C126322002 @default.
- W2617820327 hasConceptScore W2617820327C143998085 @default.
- W2617820327 hasConceptScore W2617820327C150194340 @default.
- W2617820327 hasConceptScore W2617820327C190727270 @default.
- W2617820327 hasConceptScore W2617820327C203014093 @default.
- W2617820327 hasConceptScore W2617820327C2780235182 @default.
- W2617820327 hasConceptScore W2617820327C2911091166 @default.
- W2617820327 hasConceptScore W2617820327C55493867 @default.
- W2617820327 hasConceptScore W2617820327C556039675 @default.
- W2617820327 hasConceptScore W2617820327C71924100 @default.
- W2617820327 hasConceptScore W2617820327C86803240 @default.
- W2617820327 hasConceptScore W2617820327C8891405 @default.